SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
Top Page
SOPHiA GENETICS
(NASDAQ:SOPH)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.00
▲(5.93% Upside)
Action:ReiteratedDate:03/06/26
The score is held back primarily by persistent large losses, ongoing cash burn, and a weaker 2025 balance sheet with higher leverage. Offsetting these are constructive earnings-call signals—20%–22% revenue growth guidance, improving adjusted EBITDA trajectory, and strong customer/retention metrics—while technical indicators remain broadly weak despite near-oversold readings.
Positive Factors
Platform scale & volume growth
Sustained and growing analysis volumes create durable network effects and data scale. As more institutions run NGS and multimodal tests on SOPHiA DDM, the platform benefits from stronger benchmarking, improved models, higher switching costs and recurring usage that support long-term revenue durability and product differentiation.
Negative Factors
Rising leverage
Debt more than doubled in a year while equity declined, reducing balance-sheet cushion and increasing financial risk. Higher leverage raises interest and covenant sensitivity, limits flexibility for opportunistic investments, and increases the probability of dilutive or restrictive financing if cash flow targets slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform scale & volume growth
Sustained and growing analysis volumes create durable network effects and data scale. As more institutions run NGS and multimodal tests on SOPHiA DDM, the platform benefits from stronger benchmarking, improved models, higher switching costs and recurring usage that support long-term revenue durability and product differentiation.
Read all positive factors
SOPHiA GENETICS (SOPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$338.99M
Dividend YieldN/A
Average Volume (3M)100.95K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue Growth13.66%
EPS Growth-2.65%
CountryUS
Employees423
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.28
Shares Outstanding71,668,700
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.29
Enterprise Value/Gross Profit6.37
Enterprise Value/Ebitda-5.06
Forecast
1Y Price Target
$7.00Price Target Upside48.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$88.65M
SOPHiA GENETICS Business Overview & Revenue Model
Company Description
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. It...
How the Company Makes Money
SOPHiA GENETICS primarily makes money by selling access to its SOPHiA DDM cloud software platform and related analytics applications to healthcare providers (e.g., clinical labs and hospitals) and life sciences customers (e.g., biopharma). Revenue...
SOPHiA GENETICS Key Performance Indicators (KPIs)
Any
Revenue by Segment
Reveals which parts of SOPHiA GENETICS’ business—such as platform subscriptions, consumables or services—are generating sales and profits. A large share of recurring platform revenue suggests steadier cash flow and scalable growth, while dependence on one-time product sales or a single segment increases volatility and margin risk.
Reveals which parts of SOPHiA GENETICS’ business—such as platform subscriptions, consumables or services—are generating sales and profits. A large share of recurring platform revenue suggests steadier cash flow and scalable growth, while dependence on one-time product sales or a single segment increases volatility and margin risk.
Data provided by:
The Fly
The FlySOPHiA GENETICS Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful commercial momentum: accelerating revenue growth, record new customer signings (124), strong implementation throughput (102), scalable platform improvements (1 PB processed, new DDM performance), improved adjusted gross margin (+140 bps to 74.2%), and strong retention/expansion metrics (NDR 115%, churn <1%). Management provided constructive 2026 guidance (20%–22% revenue growth) and a path toward improved adjusted EBITDA (guidance implying significant reduction in adjusted EBITDA loss). Offsetting these positives are persistent operating losses, higher reported operating expenses driven by FX movements (Swiss franc appreciation), litigation costs (~$1.8M), and the inherently long and lumpy nature of biopharma revenues and large customer implementations. Overall, the fundamentals and forward guidance show more strengths than weaknesses, but execution risks (implementation timing, FX, legal) remain and will be important to monitor.Positive Updates
Revenue Re-acceleration and 2026 Guidance
Total revenue for FY2025 was $77.3M, up 19% year-over-year. Q4 revenue was $21.7M, up 22% year-over-year. Management guided FY2026 reported revenue to $92M–$94M (20%–22% growth).
Negative Updates
Ongoing Operating Losses and Adjusted EBITDA Deficit
FY2025 operating loss was $70.9M (vs $66.6M in 2024). Adjusted EBITDA loss for 2025 was $41.5M (vs $40.2M in 2024). Q4 adjusted EBITDA loss was $9.9M (vs $9.1M in Q4 2024).
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Re-acceleration and 2026 Guidance
Total revenue for FY2025 was $77.3M, up 19% year-over-year. Q4 revenue was $21.7M, up 22% year-over-year. Management guided FY2026 reported revenue to $92M–$94M (20%–22% growth).
Read all positive updates
Company Guidance
SOPHiA GENETICS guided 2026 reported revenue of $92–94 million (20%–22% growth) and expects an adjusted EBITDA loss of $29–32 million (improving from a $41.5M adjusted‑EBITDA loss in 2025), driven by modest expansion in adjusted gross margin (2025 adjusted gross margin 74.2%) from cloud‑compute optimizations and a back‑half‑weighted ramp as large U.S. wins and MSK‑ACCESS/MSK‑IMPACT/Enhanced Exomes scale; management plans to hold OpEx in local currency while cutting discretionary spend and some headcount, expects ~60% of every incremental revenue dollar to drop to the bottom line, aims to approach adjusted‑EBITDA breakeven by end‑2026 and turn positive in H2‑2027, and finished 2025 with $70.3M cash plus roughly $14.4M of Q1 2026 ATM proceeds.SOPHiA GENETICS Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 77.27M | 65.17M | 62.37M | 47.56M | 40.45M |
| Gross Profit | 47.81M | 43.94M | 42.91M | 31.25M | 25.22M |
| EBITDA | -61.40M | -50.76M | -69.57M | -81.38M | -69.24M |
| Net Income | -79.00M | -62.49M | -78.98M | -87.45M | -73.67M |
Balance Sheet | |||||
| Total Assets | 163.46M | 155.31M | 206.16M | 243.84M | 320.17M |
| Cash, Cash Equivalents and Short-Term Investments | 70.29M | 80.23M | 123.25M | 178.61M | 265.32M |
| Total Debt | 63.02M | 30.03M | 18.60M | 16.74M | 13.06M |
| Total Liabilities | 116.31M | 58.82M | 54.71M | 43.71M | 44.77M |
| Stockholders Equity | 47.15M | 96.49M | 151.44M | 200.13M | 275.40M |
Cash Flow | |||||
| Free Cash Flow | -38.59M | -51.00M | -57.80M | -80.47M | -64.61M |
| Operating Cash Flow | -38.01M | -42.82M | -48.58M | -70.09M | -57.94M |
| Investing Cash Flow | -10.51M | -8.18M | 8.32M | 41.97M | -56.93M |
| Financing Cash Flow | 34.13M | 11.59M | -2.82M | -1.57M | 237.77M |
SOPHiA GENETICS Technical Analysis
Negative
4.72
Price Trends
4.85
Negative
4.78
Negative
4.17
Positive
Market Momentum
0.05
Negative
49.05
Neutral
32.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOPH, the sentiment is Negative. The current price of 4.72 is above the 20-day moving average (MA) of 4.65, below the 50-day MA of 4.85, and above the 200-day MA of 4.17, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 49.05 is Neutral, neither overbought nor oversold. The STOCH value of 32.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SOPH.
SOPHiA GENETICS Risk Analysis
SOPHiA GENETICS disclosed 1 risk factors in its most recent earnings report. SOPHiA GENETICS reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SOPHiA GENETICS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $776.64M | -72.16 | -7.10% | ― | 50.51% | 50.92% | |
62 Neutral | $1.80B | -166.38 | -7.41% | ― | 50.50% | ― | |
52 Neutral | $854.16M | 10.10 | -29.47% | ― | 32.90% | 1.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $338.99M | -3.99 | -116.98% | ― | 13.66% | -2.65% | |
| ― | $6.84M | -8.07 | -8.26% | ― | -24.64% | 92.19% | |
48 Neutral | $155.66M | -2.20 | -47.69% | ― | -5.30% | 46.01% |
* Healthcare Sector Average
SOPH
SOPHiA GENETICS
4.73
1.05
28.53%
SDGR
Schrodinger
11.57
-8.69
-42.89%
ZCMD
Zhongchao
1.78
-8.70
-83.02%
WGS
GeneDx Holdings
61.35
-32.99
-34.97%
DH
Definitive Healthcare Corp
1.09
-1.87
-63.18%
OMDA
Omada Health, Inc.
13.18
-9.42
-41.68%
SOPHiA GENETICS Corporate Events
SOPHiA GENETICS Posts Strong 2025 Growth and Reaffirms 2026 Outlook
Mar 3, 2026
On March 3, 2026, SOPHiA GENETICS reported that fourth-quarter 2025 revenue rose 22% year over year to $21.7 million, while full-year 2025 revenue grew 19% to $77.3 million, with adjusted gross margin improving to 74.2% despite higher data volumes...
SOPHiA GENETICS Expands Perceptive Credit Facility With New $25 Million Term Loan Capacity and Additional Warrants
Jan 28, 2026
On January 23, 2026, SOPHiA GENETICS SA amended its existing credit agreement with Perceptive Credit Holdings IV, LP, securing an additional $25 million in term loan commitments split into two $12.5 million tranches: a Tranche C loan that can be d...
SOPHiA GENETICS Announces CEO Transition and Strong Preliminary 2025 Results
Jan 12, 2026
On January 12, 2026, SOPHiA GENETICS announced a planned leadership transition, promoting President Ross Muken to Chief Executive Officer effective July 1, 2026, succeeding co-founder and current CEO Dr. Jurgi Camblong, who is expected to move int...
SOPHiA GENETICS Posts Strong 2025 Preliminary Results and Sets CEO Transition for 2026
Jan 12, 2026
On January 12, 2026, SOPHiA GENETICS reported strong preliminary, unaudited results for 2025, with full-year revenue of about $77 million, up roughly 18% year-on-year, and more than 391,000 analyses performed on its SOPHiA DDM™ platform, inc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.